Trial Profile
A Phase 2 Study to Evaluate the Safety, Tolerability and Initial Efficacy of Pramipexole ER, Given With Aprepitant in Patients With Idiopathic Parkinson's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary) ; Aprepitant
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Chase Therapeutics
- 05 Oct 2023 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 05 Oct 2023 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.
- 08 Feb 2023 Planned End Date changed from 1 Mar 2020 to 30 Dec 2023.